Pharmaceutical Technology

DECEMBER 19, 2022

Getting funding is going to be more difficult,” says Kyle Faget, partner and co-chair of Foley & Lardner’s Healthcare and Life Sciences Practices, Boston, Massachusetts. “It’s going to be a harder environment for smaller and medium biotechs. million as part of the Build Back Better Regional Challenge.

Pharmaceutical 69

Pharmaceutical Manufacturing Medicine Government 69

Contrarian Sales Techniques

FEBRUARY 26, 2023

It is noteworthy that Malaysia has a pharmaceutical manufacturing sector that almost exclusively produces generic drugs, with sales revenues amounting to only 1.5% However, they face increasing competition from foreign generic drug suppliers, which have established themselves in the market for public tenders.

Pharmaceutical 52

Pharmaceutical Medicine Government Manufacturing 52

PM360

SEPTEMBER 30, 2024

This article outlines how developers can utilize sustainability initiatives to boost revenue, reduce costs, and advance innovation, ensuring a strategic, long-term, and more sustainable position in today’s competitive landscape.

Manufacturing 52

Manufacturing Pharma Pharmaceutical Competition 52

PM360

APRIL 25, 2023

Although AbbVie’s patent for Humira officially expired in 2016, the legal and regulatory delays paused competition for Humira until 2023. pharmaceutical industry. Financial incentives were explored further in the survey as biosimilars are expected to increase competition, thereby lower cost and increase access.

Marketing 97

Marketing Competition Government Manufacturing 97

Medico Reach

FEBRUARY 8, 2023

The global pharmaceutical manufacturing market stood at USD 405.52 The paradigm shift towards integrated, intelligent, and data-rich technologies is propelling the growth of medicines manufacturing. Here are some more applications of AI in healthcare and pharma Medicines discovery and design can improve drastically.

Pharma 52

Pharma Medicine Marketing Prospecting 52

World of DTC Marketing

APRIL 12, 2021

The US Food and Drug Administration (FDA) believes the adulteration of heparin was an economically motivated act—a clear breach of the US pharmaceutical supply chain. Ironically, in later times, the intense competition for out-of-patent drugs has subsided, which has led to spiraling rises in generic drug prices and shortages.

Food and Drug Administration 187

Food and Drug Administration Prescription Pharma Manufacturing 187

European Pharmaceutical Review

FEBRUARY 20, 2025

Impact on drug pricing and affordability Increased API costs may force some manufacturers to reduce output or exit the market entirely, reducing competition and potentially driving price inflation” Rising production costs due to tariffs could lead to higher drug prices, particularly in markets where pricing pressures are already a concern.

Pharmaceutical 20

Pharmaceutical Manufacturing Medicine Pharmaceutical manufacturing 20

Clarivate

AUGUST 20, 2024

Top-line differences between list price and MFP obscure the impact of discounts and rebates that PBMs and MCOs can secure from manufacturers in exchange for coverage or preferred access. In highly competitive categories like diabetes, net price could be half of the list price.

Manufacturing 52

Manufacturing Government Prescription Pharmaceutical manufacturing 52